Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · Jun 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ZG006 for men with a rare and serious type of prostate cancer known as neuroendocrine prostate cancer (NEPC), which has spread to other parts of the body and has not responded to standard treatments. The goal is to see if ZG006 is safe and if it can help control the cancer in these patients.

Men aged 18 to 80 who have advanced NEPC that has gotten worse despite previous chemotherapy (specifically platinum-based therapy) might be eligible to join. Participants need to be well enough to take part, with a good overall health status, and have measurable cancer that doctors can track during the study. People with certain infections like HIV or hepatitis, or those the doctor feels shouldn’t participate for any reason, won’t be eligible. Since the study is still not open for recruitment, interested patients should talk to their doctor about when and how they might join. Participants will receive the new treatment and be closely monitored to understand how well it works and to check for any side effects.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male Participants aged 18 to 80 years (inclusive);
• • Advanced metastatic neuroendocrine prostate cancer;
• • disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity;
• • Measurable disease according to RECIST v1.1 criteria;
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Exclusion Criteria:
• • Known positive test for human immunodeficiency virus (HIV) or hepatitis；
• • Patients were deemed unsuitable for participating in the study by the investigator for any reason.